Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.63 |
| ▸ | MTOR | P42345 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichloroisoproterenol SCHEMBL29139831 | 1.00 | ADRB2 (0.63) | ADRB2ADRB1TSHRMAPTHIF1A | |
| SCHEMBL4628378 | 0.85 | ADRB2 (0.49) | ADRB2ADRB1TSHRMAPTHIF1A | |
| SCHEMBL11804077 | 0.83 | ADRB2 (0.55) | ADRB2ADRB1TSHRMAPTHIF1A | |
| SCHEMBL6921904 | 0.82 | CYP3A4 (0.61) | ADRB2ADRB1TSHRMAPTHIF1A | |
| Palmitic Acid SCHEMBL10780498 | 0.82 | MAPT (0.47) | ADRB2ADRB1TSHRMAPTHIF1A | |
| Hydrochloric Acid SCHEMBL11812398 | 0.82 | ADRB2 (0.56) | ADRB2ADRB1TSHRMAPTHIF1A | |
| Dichloroisoproterenol SCHEMBL28171414 | 0.81 | CYP1A2 (0.48) | ADRB2ADRB1TSHRMAPTHIF1A | |
| Hydrochloric Acid SCHEMBL8565017 | 0.81 | KDM4E (0.62) | ADRB2ADRB1TSHRMAPTHIF1A | |
| SCHEMBL10792086 | 0.81 | ALDH1A1 (0.47) | ADRB2ADRB1TSHRMAPTHIF1A | |
| SCHEMBL7152589 | 0.79 | ADRB2 (0.65) | ADRB2ADRB1TSHRHIF1AADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2017-01-05 | — | — | US | claimed |
| US-9498481-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | claimed |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-07-07 | — | — | US | claimed |
| US-9255104-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | claimed |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2014-09-25 | — | — | US | claimed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-8575348-B2 | Quinolone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC (US) | 2013-11-05 | — | — | US | claimed |
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| WO-2000040232-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2000-07-13 | — | — | WO | claimed |
| WO-1996025163-A1 | TREATMENT OF HERPES SIMPLEX VIRUSES | BOARD OF SUPERVISORS OR LOUISIANA STATE UNIVERSITYOF AGRICULTURAL AND MECHANICAL COLLEGE THROUGH ITSMEDICAL CENTER (US) | 1996-08-22 | — | — | WO | claimed |
| WO-1995032981-A1 | NOVEL GLYCOSIDE COMPOUNDS AND PRODUCTION AND USE THEREOF | HARRIER, INC. (US) | 1995-12-07 | — | — | WO | claimed |
| US-4898729-A | Treatment of hypertension, compounds and compositions for antihypertension and diuresis | EUROCELTIQUE, S.A. (LU) | 1990-02-06 | — | — | US | claimed |
| EP-0073819-B1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | The University of Kentucky Research Foundation (US) | 1987-05-27 | — | — | EP | claimed |
| EP-0154009-A1 | Use of a thiazide diuretic for the manufacture of a non-diuretic antihypertensive medicament | Euro-Celtique S.A. (LU) | 1985-09-11 | — | — | EP | claimed |
| EP-0073819-A4 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1984-11-16 | — | — | EP | claimed |
| US-4428883-A | NASAL OINTMENTS OR GELS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-01-31 | — | — | US | claimed |
| EP-0073819-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1983-03-16 | — | — | EP | claimed |
| WO-1982003009-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | UNIV KENTUCKY RES FOUND (US) | 1982-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ADRB2 180/4885ADRB1 152/4885TSHR 1128/4885 |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ADRB2 180/4885ADRB1 152/4885TSHR 1128/4885 |
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ADRB2 142/4885ADRB1 134/4885TSHR 959/4885 |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | ADRB2 1422/4885ADRB1 1713/4885TSHR 3285/4885 |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ADRB2 180/4885ADRB1 152/4885TSHR 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.